US Pharma MarketingCancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the…
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug's safety profile has previously been one of its main potential selling points. But Wall Street was rattled by malignancy ...
Source: Endpoints News